Drugs / MR-MC-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04610359 | Oct 2020 → Oct 2022 | interstitial cystitis | Asan Medical Center | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MR-MC-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04610359 ↗ |
| Modality | Cell therapy | “MR-MC-01, a mesenchymal stem cell therapy derived from human embryonic stem cells” PMID 40387787 ↗ May 2025 |
| Route | Other | “Submucosal injection” NCT04610359 ↗ |